In English
NIDA

Personas con VIH o SIDA

Study Endorses Onsite HIV Testing Without Risk Reduction Counseling

Patients were more likely to take a rapid HIV test when substance abuse treatment programs offered the test onsite rather than referred for offsite testing. Patients were equally likely to accept and learn their HIV status whether the offer of onsite testing was accompanied by 30 minutes of risk reduction counseling or by 5 minutes of brief information on the testing procedure. Onsite testing accompanied by brief information was cost effective, taking into account the projected lifetime costs of treatment and the gains in health and longevity for detected cases.

Seek-Test-Treat-Retain To Stop the Spread of HIV

NIDA Director Nora Volkow

Despite the advances in treatment and prevention, roughly 50,000 new HIV infections still occur annually in the Nation. Research, in large part supported by NIDA, has produced a strategy to address this circumstance and break the epidemiological impasse: seek out HIV-infected individuals, particularly those in “hard-to-reach” groups that have minimal contact with the health care system; offer them HIV testing and treatment; and provide support to help them stay in treatment.

Antiretroviral Treatment Reduces Spread of HIV Among Injection Drug Users

Expanded use of antiretroviral therapy in British Columbia reduced the spread of HIV among injection drug users and others in the province.

Journal Highlights Global Nexus of Drug Abuse and HIV/AIDS

Reviews a journal supplement that compiles studies on drug-related HIV transmission, with a focus on injection drug use, in 16 different localities across the globe.

HIV Patients Show Better Immune Recovery With Early Initiation of HAART

Presents evidence that among men and women with HIV, those who received early initiation of HAART therapy, those with higher CD4+ levels, achieved better immune recovery.

Researchers Report on Progress of NIDA's Southern Africa Initiative

Presents an update on NIDA’s Southern African Initiative, a program that aims to build research capacity and infrastructure in the area of addiction, particularly drug-related HIV transmission.

Selenium Shows Promise as an Adjunct Therapy for HIV

Reports on a randomized controlled trial of HIV-infected men and women who, as a result of receiving selenium supplements, experienced lower HIV viral load and greater CD4 cell count.

DESPR Identifies Drug Abuse Trends and Seeks Solutions

Discusses the work of NIDA’s Division of Epidemiology, Services and Prevention Research, organized to track drug use and provide empirically based information for researchers and service providers.

Study Gives Green Light to Antiretroviral Medications for HIV-Infected Injection Drug Users

Reports finding from a study showing that access to antiretroviral therapies, HAART in particular, can improve the health of HIV-infected patients who have a history of injection drug use.

Pages

Subscribe to RSS - Personas con VIH o SIDA

Attention

Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at

Toma el reto nacional sobre el coeficiente intelectual (CI) sobre las drogas